Copenhagen offers extraordinary buisiness opportunities to pharmaceutical companies within the areas of: Diabetes , Inflammation/immunology, Neuroscience and Cancer.
Here, you can read about the areas in which Copenhagen offers extraordinary buisiness opportunities to pharmaceutical companies:
- Diabetes
- Inflammation/immunology
- Neuroscience
- Cancer
1. The world leader in diabetes
Medicon Valley is one of the strongest regions in the world for diabetes research. In an international benchmark performed by the Boston Consulting Group, Medicon Valley scored highest against Boston and Seattle in the commercial attractiveness of its diabetes research.
Novo Nordisk, one of the world’s two major diabetes companies, anchors this research, but the region also contains many other diabetes firms. The region’s world-class academic research groups cover the entire field from the molecular to the epidemiological level.
Corporate R&D expenditures are close to half a billion USD annually, mainly from Novo Nordisk, with academic expenditures of USD 16 million, mainly from Lund University.
The region’s thriving academic environment in health and technology, the high impact of its research and its strong pharmaceutical industry combine to make it ideal as a location for biotech companies.
2. Strong basic immunology and inflammation research
Corporate expenditures on R&D in immunology and inflammation amount to USD 120 million a year, and academic research centered in Copenhagen reaches USD 13 million a year.
AstraZeneca’s presence in Medicon Valley is the main reason why the Boston Consulting Group considers the area to be on a par with San Diego and Boston as a world-leading stronghold of immunology and inflammation research. Medicon Valley’s wide-ranging academic research groups in the field also make a strong contribution to regional expertise.
AstraZeneca’s presence ensures a critical mass of respiratory and inflammatory research. Other contributing companies include Active Biotech, Genmab, Pharmexa, and ALK-Abelló.
3. Global leadership in applied neuroscience
About USD 33 million is spent on academic neuroscience research in Medicon Valley every year, supporting approximately 200 Ph.Ds. According to the Boston Consulting Group, one of the strengths in neuroscience is applied tissue repair, and in this field, the region is at the forefront.
H. Lundbeck, one of the world’s leading producers of anti-depressants, anchors another Medicon Valley research stronghold: Neuroscience. H. Lundbeck alone devotes USD 200 million to R&D every year and employs 750 researchers. Other neuroscience companies include Maxygen, NeuroSearch, and Pharmexa.
4. A European leader in cancer research
In Europe, no other cluster can match Medicon Valley’s strong combination of pharmaceutical and biotech companies active in cancer research.
According to the Boston Consulting Group, Medicon Valley is probably the strongest region in Europe for cancer R&D. The region’s output of quality publications and the size of its cancer research community shine brightly in international comparisons.
The regional academic cancer research spending is no less than USD 37 million annually for 400 Ph.Ds. Corporate research spending is USD 50 million. Moreover, Medicon Valley’s cancer research includes cell cycle and laminin-cell studies that are internationally known.
